Rummelt Andreas 4

Accession 0000899866-21-000064

CIK 0000899866other

Filed

Jul 22, 8:00 PM ET

Accepted

Jul 23, 4:34 PM ET

Size

16.4 KB

Accession

0000899866-21-000064

Form 4

Period: 2021-07-21

Director

Transactions

Disposition to Issuer
Common Stock, par value $.0001 per share
2021-07-21−28,109→ 0 total
Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$155.01/sh−2,343$363,188→ 0 total
Exercise: $155.01From: 2016-05-06Exp: 2025-05-06→ Common Stock, par value $.0001 per share (2,343 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$159.70/sh−2,785$444,764→ 0 total
Exercise: $159.70From: 2015-05-05Exp: 2024-05-05→ Common Stock, par value $.0001 per share (2,785 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$96.35/sh−3,425$329,999→ 0 total
Exercise: $96.35From: 2013-08-07Exp: 2023-05-07→ Common Stock, par value $.0001 per share (3,425 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$138.86/sh−2,294$318,545→ 0 total
Exercise: $138.86From: 2017-05-11Exp: 2026-05-11→ Common Stock, par value $.0001 per share (2,294 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2021-07-21$85.75/sh−3,237$277,573→ 0 total
Exercise: $85.75From: 2012-08-08Exp: 2022-05-08→ Common Stock, par value $.0001 per share (3,237 underlying)

Footnotes (2)

[F1]Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
[F2]Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.

Documents

1 file

ALEXION PHARMACEUTICALS, INC.

CIK 0000899866

Entity typeother